Loading Complete
Theodoros Karantanos

Theodoros Karantanos, MD, PhD

Hematology Oncology

Johns Hopkins Affiliations:
  • Johns Hopkins School of Medicine Faculty

Languages

  • Greek
  • English

14 Insurances Accepted

View all

Gender

Male

About Theodoros Karantanos

Primary Academic Title

Assistant Professor of Oncology

Background

Dr. Karantanos graduated from the School of Health Sciences at the University of Athens, Greece and received a Ph.D. in cancer biology. As a post-doctoral research fellow at MD Anderson Cancer Center/University of Texas, he studied signal transduction in cancer and developed expertise in mouse modeling and targeted therapies. He completed his internal medicine residency and Chief residency training at Boston University and his medical oncology fellowship training at Johns Hopkins. His clinical research focused on sex-related differences in the genomic profile and outcomes of MPN and MDS/MPN patients. As a research fellow he studied malignant hematopoiesis and his work led to the identification of CCRL2, as an inducer of MDS/sAML cells growth and a mediator of azacitidine resistance.

Research Interests

Molecular biology of MDS and AML

Research Summary

My research focuses on the dissection of growth signaling regulation in MDS and MDS/MPN and mechanisms implicated in the progression of chronic myeloid diseases to AML. My work incorporates gene editing by CRISPR-Cas9, signal transduction analysis, progenitor assays, drug screens and MDS/AML xenograft models.

Our lab studies the molecular biology of growth signaling regulation in MDS and MDS/MPN and investigates novel therapies that can effectively target these pathways using in vitro and in vivo models.

Selected Publications

  • Karantanos T, Chaturvedi S, Braunstein EM, Spivak JL, Resar L, Karanika S, Williams D, Rogers O, Gocke C, Moliterno AR. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv. 2020 Jun 23;4(12):2567-2576

  • Karantanos T, Gondek LP, Varadhan R. Moliterno AR, Dezern AE, Jones RJ, Jain T. Gender-related differences in the outcomes and genomic landscape of patients with MDS/MPN. Br J Haematol. 2021 Jun;193(6):1142-1150

  • Karantanos T, Teodorescu P, Arvanitis M, Perkins B, Jain T, DeZern AE, Dalton WB, Christodoulou I, Paun BC, Varadhan R, Esteb C, Rajkhowa T, Bonifant C, Gondek LP, Levis MJ, Yegnasubramanian S, Ghiaur G, Jones RJ. CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine. Haematologica. 2022 Dec 15

  • Karantanos T, Teodorescu P, Perkins B, Christodoulou I, Esteb C, Varadhan R, Helmenstine E, Rajkhowa T, Paun BC, Bonifant C, Dalton WB, Gondek LP, Moliterno AR, Levis MJ, Ghiaur G, Jones RJ. The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. Sci Adv. 2022 Feb 18;8(7):eabl8952

  • Karantanos T, Tsai HL, Gondek LP, DeZern AE, Ghiaur G, Dalton WB, Gojo I, Prince GT, Webster J, Ambinder A, Smith BD, Levis MJ, Varadhan R, Jones RJ, Jain T. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leuk Lymphoma. 2022 Aug;63(8):1942-1948

Honors

  • K08 Clinical Scientist Research Career Development Award, NIH/NHLBI, 4/24/23
  • Passano Award, Passano Foundation, 3/1/23
  • Clinician Scientist Award, Johns Hopkins University, 1/1/23
  • MacMillan Pathway to Independence Program, Sidney Kimmel Cancer Center, 7/1/22
  • Research Training Award for Fellows, American Society of Hematology, 7/1/21
  • Physician Scientist Johns Hopkins Training Program Grant, 1/1/21
  • T32 Training Program in Hematology, Johns Hopkins University, 7/1/19
  • Prostate Cancer Foundation (PCF) Young Investigator Award, 5/1/13
  • Hellenic Society of Medical Oncology Young Investigator Award, 7/1/12

Memberships

  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • American Society of Transplantation and Cellular Therapy

Professional Activities

  • Leukemia Service Attending

Locations

  1. The Johns Hopkins Hospital
    • 1800 Orleans Street, Baltimore, MD 21287

    Expertise

    Education

    Johns Hopkins University School of Medicine

    Fellowship, Oncology, 2022

    Boston Medical Center

    Residency, Internal Medicine, 2017

    National and Kapodistrian University of Athens

    Graduate School, Cancer Biology, PhD, 2016

    National and Kapodistrian University of Athens

    Medical Education, MD, 2011

    Board Certifications

    Medical Oncology

    American Board of Internal Medicine, 2020

    Internal Medicine

    American Board of Internal Medicine, 2017

    Insurance

    Johns Hopkins providers accept various commercial health insurance plans. However, they may not be included in all of an insurance company's plans or offerings. This may include Exchange, Medicaid, Medicare, and specific limited benefit plans. Exceptions to participation also exist based on your employer’s benefits package and the provider's location or specialty. Please contact your insurer directly to make sure your doctor is covered by your plan. For more details, please review our Insurance Information.
    Search plans
    • Aetna
    • CareFirst
    • Cigna
    • First Health
    • Geisinger Health Plan
    • HealthSmart/Accel
    • Humana
    • Johns Hopkins Health Plans
    • MultiPlan
    • Pennsylvania's Preferred Health Networks (PPHN)
    • Point Comfort Underwriters
    • Private Healthcare Systems (PHCS)
    • UnitedHealthcare
    • Veteran Affairs Community Care Network (Optum-VACCN)